Mechanism of Action
MOR and DOR Activation
Both MOR and DOR are Gi-coupled GPCRs that inhibit adenylyl cyclase, activate inwardly rectifying K+ channels (causing hyperpolarization), and block voltage-gated Ca2+ channels, reducing neurotransmitter release. Enkephalins at MOR produce analgesia and euphoria (weaker than morphine due to rapid degradation). At DOR, enkephalins produce analgesia, anxiolysis, and antidepressant effects through distinct circuits -- DOR is expressed in limbic and cortical regions involved in emotion processing.
Enkephalinase and Tonicity
Enkephalins are rapidly degraded by two metallopeptidases: neutral endopeptidase (NEP/neprilysin) and aminopeptidase N (APN). Inhibiting these enzymes amplifies endogenous enkephalin signaling specifically at synapses where enkephalin is released, providing spatially targeted enhancement without the systemic exposure and tolerance issues of exogenous opioids. Racecadotril (enkephalinase inhibitor) reduces intestinal secretion and is used for acute diarrhea.
Research Summary
DOR Agonists for Pain and Depression
Phase 2DOR-selective agonists (SNC80, BU48, KNT-127) produce antinociception and antidepressant effects in animal models without the abuse liability of MOR agonists. Phase 2 trials of DOR agonists have demonstrated analgesic and antidepressant signals. DOR activation reduces neuroinflammation and promotes neuroplasticity -- mechanisms relevant to treatment-resistant depression. DOR agonists do not produce respiratory depression at analgesic doses, a key safety advantage.
Enkephalinase Inhibitors
Approved (Some Countries)Racecadotril (acetorphan) inhibits enkephalinase in gut enteroendocrine cells, potentiating local enkephalin-mediated reduction of intestinal secretion. Approved in France and many countries for acute diarrhea in children and adults; superior to loperamide in some metrics. Confirms that enhancing endogenous enkephalin tone has therapeutic value with minimal CNS penetration and abuse potential.
Acupuncture and Endogenous Release
Active ResearchAcupuncture and other somatosensory stimulation paradigms increase enkephalin release in the spinal cord and brainstem. Naloxone (opioid antagonist) partially blocks acupuncture analgesia, implicating endogenous opioids. Electroacupuncture at 2 Hz preferentially releases enkephalin (MOR/DOR) while 100 Hz releases dynorphin (KOR). Understanding endogenous enkephalin release may optimize non-pharmacological pain management.
Calculate your Enkephalin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Pain research (spinal) | 1-20 nmol intrathecal in rodents | Per session | Intrathecal |
| DOR research (behavioral) | 5-20 nmol ICV; 1-10 mg/kg IP (for stable analogs) | Per session | ICV or intraperitoneal |
Native enkephalins are rapidly degraded in vivo. Stable DOR-selective analogs (DPDPE, deltorphin) are preferred for sustained research effects. Enkephalinase inhibitors prolong endogenous enkephalin action.
Interactions
Safety Profile
Exogenous enkephalins are poorly suited for systemic use due to rapid enzymatic degradation. Research doses via intrathecal/ICV routes in animals produce analgesia and sedation without respiratory depression at DOR-selective doses. Stable DOR agonists in Phase 2 trials show acceptable tolerability with primary adverse effects of mild sedation and GI effects. Enkephalinase inhibitors (racecadotril) are well tolerated with GI effects only. The short half-life of native enkephalins essentially eliminates systemic abuse potential.
References
- [1]Hughes J, et al. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature. 1975;258(5536):577-580.
- [2]Kieffer BL, Evans CJ. Opioid receptors: from binding sites to visible molecules in vivo. Neuropharmacology. 2009;56(Suppl 1):205-212.